128 related articles for article (PubMed ID: 21731080)
1. Neuropharmacological approach against MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine)-induced mouse model of Parkinson's disease.
Yokoyama H; Kuroiwa H; Kasahara J; Araki T
Acta Neurobiol Exp (Wars); 2011; 71(2):269-80. PubMed ID: 21731080
[TBL] [Abstract][Full Text] [Related]
2. Continuous MPTP intoxication in the Göttingen minipig results in chronic parkinsonian deficits.
Nielsen MS; Glud AN; Møller A; Mogensen P; Bender D; Sørensen JC; Doudet D; Bjarkam CR
Acta Neurobiol Exp (Wars); 2016; 76(3):199-211. PubMed ID: 27685773
[TBL] [Abstract][Full Text] [Related]
3. Neuroprotective effect of the chemical chaperone, trehalose in a chronic MPTP-induced Parkinson's disease mouse model.
Sarkar S; Chigurupati S; Raymick J; Mann D; Bowyer JF; Schmitt T; Beger RD; Hanig JP; Schmued LC; Paule MG
Neurotoxicology; 2014 Sep; 44():250-62. PubMed ID: 25064079
[TBL] [Abstract][Full Text] [Related]
4. A novel anti-Parkinsonian agent, zonisamide, attenuates MPTP-induced neurotoxicity in mice.
Yano R; Yokoyama H; Kuroiwa H; Kato H; Araki T
J Mol Neurosci; 2009 Sep; 39(1-2):211-9. PubMed ID: 19199078
[TBL] [Abstract][Full Text] [Related]
5. Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson's disease.
Liu LX; Chen WF; Xie JX; Wong MS
Neurosci Res; 2008 Feb; 60(2):156-61. PubMed ID: 18054104
[TBL] [Abstract][Full Text] [Related]
6. Protection of dopaminergic neurons with a novel astrocyte modulating agent (R)-(-)-2-propyloctanoic acid (ONO-2506) in an MPTP-mouse model of Parkinson's disease.
Kato H; Araki T; Imai Y; Takahashi A; Itoyama Y
J Neurol Sci; 2003 Apr; 208(1-2):9-15. PubMed ID: 12639719
[TBL] [Abstract][Full Text] [Related]
7. Role of reactive nitrogen and reactive oxygen species against MPTP neurotoxicity in mice.
Yokoyama H; Takagi S; Watanabe Y; Kato H; Araki T
J Neural Transm (Vienna); 2008 Jun; 115(6):831-42. PubMed ID: 18235988
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
Shin JY; Park HJ; Ahn YH; Lee PH
J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187
[TBL] [Abstract][Full Text] [Related]
9. Neuroprotection in Parkinson models varies with toxin administration protocol.
Anderson DW; Bradbury KA; Schneider JS
Eur J Neurosci; 2006 Dec; 24(11):3174-82. PubMed ID: 17156378
[TBL] [Abstract][Full Text] [Related]
10. Riluzole (2-amino-6-trifluoromethoxy benzothiazole) attenuates MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice.
Araki T; Muramatsu Y; Tanaka K; Matsubara M; Imai Y
Neurosci Lett; 2001 Oct; 312(1):50-4. PubMed ID: 11578843
[TBL] [Abstract][Full Text] [Related]
11. Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice.
Sathiya S; Ranju V; Kalaivani P; Priya RJ; Sumathy H; Sunil AG; Babu CS
Neuropharmacology; 2013 Oct; 73():98-110. PubMed ID: 23747572
[TBL] [Abstract][Full Text] [Related]
12. Biochemical alterations of the striatum in an MPTP-treated mouse model of Parkinson's disease.
Kuroiwa H; Yokoyama H; Kimoto H; Kato H; Araki T
Metab Brain Dis; 2010 Jun; 25(2):177-83. PubMed ID: 20431930
[TBL] [Abstract][Full Text] [Related]
13. Atractylon, a novel dopamine 2 receptor agonist, ameliorates Parkinsonian like motor dysfunctions in MPTP-induced mice.
Li H; Wang F; Zhou Z; Jiang X; Li F; Feng Y; Liu C; Zhang Y; Fan S; Wu X; Huang C
Neurotoxicology; 2022 Mar; 89():121-126. PubMed ID: 35104500
[TBL] [Abstract][Full Text] [Related]
14. Anti-inflammatory and neuroprotective effects of an orally active apocynin derivative in pre-clinical models of Parkinson's disease.
Ghosh A; Kanthasamy A; Joseph J; Anantharam V; Srivastava P; Dranka BP; Kalyanaraman B; Kanthasamy AG
J Neuroinflammation; 2012 Oct; 9():241. PubMed ID: 23092448
[TBL] [Abstract][Full Text] [Related]
15. Neuroprotective effects of acetyl-l-carnitine (ALC) in a chronic MPTP-induced Parkinson's disease mouse model: Endothelial and microglial effects.
Burks S; Raymick J; Robinson B; Hanig J; Sarkar S
Neurosci Lett; 2019 Jun; 703():86-95. PubMed ID: 30890473
[TBL] [Abstract][Full Text] [Related]
16. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
[TBL] [Abstract][Full Text] [Related]
17. Toxicity of MPTP on neurotransmission in three mouse models of Parkinson's disease.
Pain S; Gochard A; Bodard S; Gulhan Z; Prunier-Aesch C; Chalon S
Exp Toxicol Pathol; 2013 Jul; 65(5):689-94. PubMed ID: 23083629
[TBL] [Abstract][Full Text] [Related]
18. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
19. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease.
Breidert T; Callebert J; Heneka MT; Landreth G; Launay JM; Hirsch EC
J Neurochem; 2002 Aug; 82(3):615-24. PubMed ID: 12153485
[TBL] [Abstract][Full Text] [Related]
20. Progressive dopaminergic degeneration in the chronic MPTPp mouse model of Parkinson's disease.
Schintu N; Frau L; Ibba M; Garau A; Carboni E; Carta AR
Neurotox Res; 2009 Aug; 16(2):127-39. PubMed ID: 19526289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
